Recurrent Squamous Cell Carcinoma of the Larynx Active Not Recruiting Phase 1 / 2 Trials for Cetuximab (DB00002)

IndicationStatusPhase
DBCOND0028811 (Recurrent Squamous Cell Carcinoma of the Larynx)Active Not Recruiting1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01816984PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck CancerTreatment